Wallmann, Georg https://orcid.org/0000-0003-4749-3730
Skowronek, Patricia https://orcid.org/0000-0002-8441-6067
Brennsteiner, Vincenth
Lebedev, Mikhail https://orcid.org/0009-0008-3646-7899
Thielert, Marvin
Steigerwald, Sophia
Kotb, Mohamed
Despard, Oscar
Heymann, Tim https://orcid.org/0000-0002-6984-6894
Zhou, Xie-Xuan
Strauss, Maximilian T. https://orcid.org/0000-0003-3320-6833
Ammar, Constantin
Willems, Sander https://orcid.org/0000-0002-7124-610X
Schwörer, Magnus
Zeng, Wen-Feng https://orcid.org/0000-0003-4325-2147
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Funding for this research was provided by:
Max-Planck-Gesellschaft
EC | Horizon 2020 Framework Programme (874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839, 874839)
Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-bayern.de).
Article History
Received: 25 June 2024
Accepted: 24 July 2025
First Online: 21 October 2025
Competing interests
: M.M. is an indirect investor in Evosep. G.W. is founder of Aplusia, a biotech consultancy. The other authors declare no competing interests.